An SMN1 Carrier Result and SMA: What One Variant Really Means When You’re Pregnant

An SMN1 Carrier Result and SMA: What One Variant Really Means When You’re Pregnant

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Decades of genetic and public-health evidence show that spinal muscular atrophy (SMA) is an autosomal recessive single-gene disorder of the SMN1 gene. It appears only when a child inherits two non-working copies. Carrying one SMN1 variant, as a 23andMe report may flag, makes you a healthy carrier, not a patient. Your result matters for reproductive planning, and only if your partner is also a carrier. The same research explains why newborn screening and three approved therapies have transformed the outlook.

What you’ll learn

• Why one SMN1 variant makes you a carrier, not a person with SMA.
• The exact recurrence-risk numbers if your reproductive partner is also a carrier.
• How US and Canada testing and newborn screening work, and where a 23andMe result falls short.
• The honest treatment status, including approval dates and what “cure” headlines get wrong.

How SMA Is Inherited: The SMN1 Gene, SMN2 Copy Number, and Recessive Transmission

Spinal muscular atrophy is caused by changes in a single gene called SMN1, located on chromosome 5. This gene carries the recipe for the survival motor neuron (SMN) protein, which keeps motor neurons alive and healthy. Motor neurons are the nerve cells that tell muscles to move. When both copies of SMN1 stop working, those cells lose the protein they need and begin to fail. That one job, done or not done, sits at the center of everything else here.

SMA follows autosomal recessive inheritance. That phrase means a person needs two non-working copies of the gene, one from each parent, before the disorder appears. Everyone carries two copies of SMN1. A carrier has one working copy and one non-working copy. The single working copy makes enough protein, so a carrier stays healthy and has no symptoms. Picture a two-burner stove where only one burner lights: it still cooks the meal, just with less capacity to spare. An affected child instead inherits a non-working copy from each parent, and has no working SMN1 at all.

Most people with SMA are missing exon 7 of both SMN1 copies. Research shows that roughly 94-95% of people with SMA lack both copies of SMN1 exon 7, a change called a homozygous deletion. The rest carry rarer point mutations or gene-conversion events. This detail matters for testing, because different tests look for different things, a point a later section returns to.

SMA has a twist that most gene disorders do not. A nearly identical backup gene, called SMN2, sits right next to SMN1. SMN2 differs from SMN1 by a single letter in exon 7, and because of that letter it makes only a small amount of working SMN protein, less than 10% of the total. Here is the key point: the number of SMN2 copies a person has, often 1 to 4, strongly shapes how severe SMA is. More SMN2 copies generally mean a milder, later-onset disease. This is why clinical reports list both SMN1 status and SMN2 copy number.

One practical caution applies to consumer reports. A 23andMe carrier report detects only the common SMN1 exon-7 deletion and does not report SMN2 copy number. It also cannot see rarer point mutations. So it is a screening flag, not a diagnosis. A board-certified genetic counselor, found through the National Society of Genetic Counselors at NSGC.org, can explain which test fits your situation.

Section recap: SMA comes from two non-working copies of the SMN1 gene, so a single-variant carrier stays healthy. The backup gene SMN2, and how many copies of it a person has, strongly modifies how severe the disease is.

Risk Magnitude: Carrier Frequency, the 25% Rule, and Near-Complete Penetrance

Genetics can feel abstract, so it helps to turn the odds into plain counts. The key rule comes from recessive inheritance. If both reproductive partners are SMN1 carriers, each pregnancy carries fixed probabilities. There is a 25% chance the child inherits two non-working copies and is affected. There is a 50% chance the child is a carrier like the parents. There is a 25% chance the child inherits two working copies and is neither.

Translated to counts, imagine 100 pregnancies between two carrier parents. On average, the outcomes break down like this:

• About 25 out of 100 children would have SMA (two non-working copies).
• About 50 out of 100 would be healthy carriers, just like their parents.
• About 25 out of 100 would carry no variant at all.

These are averages across many pregnancies, not a schedule. A common misread is to assume that once a carrier couple has one affected child, the “next three are safe.” That is not how it works. Each pregnancy still faces the same independent 1-in-4 chance, the same way each coin flip stays 50-50 no matter what came before.

Now consider a single carrier, like a reader who saw one SMN1 flag on a 23andMe report. Being a carrier means your own risk of having SMA is essentially zero, because you have a working copy. Recurrence risk only becomes relevant if your reproductive partner is also an SMN1 carrier. Your result is a piece of family-planning information, not a personal diagnosis. That is worth holding onto if you are pregnant and anxious: the next practical move is your partner’s status, not your own health.

How common is carrier status in the first place? Primary sources put concrete numbers on it:

Measure	Approximate figure	Source
Carrier frequency (most populations)	About 1 in 40 to 1 in 60
SMA incidence at birth	About 1 in 6,000 to 1 in 11,000

To make the carrier number tangible: if about 1 in 50 people carries an SMN1 deletion, then in a full school classroom of children, on average one child’s parent might be a carrier without ever knowing it. That is exactly why professional groups now recommend offering screening to everyone, not only those with a family history.

SMA also behaves differently from many gene results people worry about. When a child inherits no working SMN1, developing SMA has essentially complete penetrance, meaning the disease reliably follows. Penetrance is simply how often a gene result actually produces its effect. But SMA adds a second layer: SMN2 copy number and, critically, early treatment now change how severe the disease is. So onset is near-certain, yet the outcome is no longer fixed. A genetic counselor can put your own numbers in context.

Section recap: For two carrier parents, each pregnancy has a 25% chance of an affected child, so about 25 of 100. A single carrier faces essentially zero personal risk, and carrier frequency is roughly 1 in 40 to 60.

What a 23andMe SMN1 Carrier Result Actually Means, and Its Limits

This is the question that brings most readers here, so it deserves a direct answer. A single SMN1 carrier finding on a direct-to-consumer report means you are a healthy, unaffected carrier. You have one working copy of the gene, which makes enough SMN protein, so you have no personal risk of developing SMA. The result is relevant only to reproductive planning, and only once your partner’s carrier status is known. If you are already pregnant, that reframing is the calm center of the whole picture.

But the test has real limits, and understanding them prevents both false alarm and false comfort. A 23andMe report screens for the common SMN1 exon-7 deletion using a copy-number assay, which counts how many working SMN1 copies you have. That approach works well for typical carriers. It runs into trouble with a special configuration called a “silent” or “2+0” carrier.

Here is what that means in plain terms. A silent 2+0 carrier has two SMN1 copies sitting together on one chromosome and zero copies on the other. A copy-number test counts two copies total and can report “not a carrier,” even though this person truly is one. Research puts the size of this blind spot at roughly 3-5% of carriers commonly cited, and up to about 3-9% in non-African-ancestry populations, with a much higher fraction, around 27%, in people of African ancestry. Rare point mutations are also not covered by a basic consumer screen.

The takeaway is a two-sided one. A positive DTC flag is a real reason to seek clinical confirmation, not a diagnosis by itself. And a negative DTC result reduces your carrier risk but does not fully eliminate it, especially depending on ancestry. Both readings point to the same next step: confirm anything that matters for a pregnancy in a CLIA-certified or accredited clinical lab, and talk it through with a board-certified genetic counselor before drawing conclusions. Treating a single consumer line as the final word is like reading one page of a report and assuming you know the ending.

Section recap: A single SMN1 flag makes you a healthy carrier with no personal SMA risk; it matters only for reproduction once your partner is tested. Consumer copy-number screens miss silent 2+0 carriers and rare mutations, so confirm results clinically.

Testing Options: Molecular SMN1/SMN2 Testing, Carrier Screening, and Prenatal Choices

A US or Canada reader meets SMA testing in several different settings, and sorting them out prevents needless worry. They are not interchangeable: one confirms and quantifies the gene, one screens couples before or during pregnancy, one is a limited consumer product, and some apply only to a pregnancy already underway. The table below lays them side by side.

Testing setting	What it checks	Strengths and cautions	Diagnostic?
Molecular SMN1/SMN2 testing	SMN1 copy number plus SMN2 copy number, via MLPA or qPCR	Gold standard in a CLIA-certified or accredited lab; SMN2 count adds prognosis	Yes — confirms carrier or affected status
Carrier screening (pre- or during pregnancy)	SMN1 copy number for prospective or pregnant parents	ACOG and ACMG recommend offering it to all women, any ancestry	Screening; residual risk remains from silent carriers
Direct-to-consumer report (23andMe)	Common SMN1 exon-7 deletion only	Not diagnostic; misses silent 2+0 carriers and rare mutations	No — confirm concerning results clinically
Prenatal / pre-pregnancy options	The specific SMN1 variants in a known carrier couple	CVS, amniocentesis, or PGT-M; only for couples both confirmed as carriers	Yes, in the pregnancy or embryo context

Molecular SMN1/SMN2 testing is the gold standard. Run in a CLIA-certified or accredited laboratory, it uses quantitative methods such as MLPA or qPCR to count SMN1 copies precisely, which is how a suspected case or a carrier flag is confirmed. Crucially, diagnostic testing also reports SMN2 copy number, which helps predict how severe the disease might be. This is the tool that turns an uncertain consumer result into a clear answer.

Carrier screening is the next context. Professional guidance from ACOG recommends offering SMA carrier screening to all women who are considering pregnancy or are already pregnant, regardless of ancestry. This 2017 guidance was the first ACOG recommendation to extend SMA screening beyond those with a known family history. Genetic counseling is part of the package, because a normal copy-number result reduces but does not erase the residual risk from silent 2+0 carriers and rare point mutations.

Prenatal and pre-pregnancy options apply only once both partners are confirmed carriers. During a pregnancy, chorionic villus sampling (CVS) or amniocentesis with molecular testing can determine whether the fetus is affected. Before a pregnancy, preimplantation genetic testing for monogenic disease (PGT-M), used with in vitro fertilization, can select unaffected embryos. For a reader who is already pregnant, the most useful move is prompt SMN1 carrier testing for the partner, then a conversation about prenatal options with a clinician. Your obstetrician, primary care physician, or a genetic counselor at NSGC.org can arrange the right test.

Section recap: Clinical MLPA/qPCR testing counts SMN1 and SMN2 copies and is the gold standard; ACOG recommends offering carrier screening to all women. Consumer panels are limited, and CVS, amniocentesis, or PGT-M apply once both partners are confirmed carriers.

Newborn Screening: SMA Is Now Standard on the US RUSP and Expanding in Canada

The persona’s specific worry, whether her baby will be checked automatically, deserves a clear and largely reassuring answer. In the United States, SMA was added to the federal Recommended Uniform Screening Panel (RUSP) in July 2018. The RUSP is the list of core conditions that the Health Resources and Services Administration advises states to screen for using the standard newborn dried-blood-spot. By the mid-2020s essentially all 50 US states had adopted SMA newborn screening. So in the US, an affected baby can usually be identified before any symptoms appear.

In Canada, the picture depends on where you live. Newborn screening is administered province by province, not by one national program. SMA has been progressively added across provinces, including Ontario, but coverage still varies by jurisdiction. A Canadian reader should confirm her own provincial newborn-screening program rather than assume automatic testing. A clinician or genetic counselor can tell you what your province currently screens for.

There is one technical limit worth knowing. Newborn screening detects the common homozygous SMN1 exon-7 deletion, but it does not by itself establish SMN2 copy number. SMN2 counting is added on confirmatory diagnostic testing after a positive screen. In other words, screening flags the babies who need a closer look; the full picture comes from the follow-up test.

Why does all this matter so much? Because SMA type 1, the most severe infantile form, causes rapid and irreversible loss of motor neurons in the first months of life. Once those cells are gone, they do not come back. Identifying and treating affected infants before symptoms start is the single biggest driver of better outcomes, which is precisely why SMA was added to newborn screening. Think of it like a smoke detector: the value is not in reacting to a fully involved fire, but in catching it while there is still time to act. If your baby’s screen is ever positive, a pediatric neurology or metabolic specialist should lead what comes next.

Section recap: In the US, SMA has been on the RUSP since July 2018 and essentially all states screen newborns; in Canada it varies by province and is expanding. Screening finds affected babies before symptoms, which is when treatment helps most.

Treatment Landscape: Nusinersen, Onasemnogene Abeparvovec, and Risdiplam

Here honesty about the details matters most, because this is where headlines mislead. Three disease-modifying therapies now exist for SMA, each with a different mechanism, route, and approval date. Two work by boosting the SMN protein made from the backup SMN2 gene, and one replaces the missing SMN1 gene directly. The table below lays out what the primary evidence and regulators actually establish.

Therapy (brand)	How it works	Route	FDA approval	Health Canada approval	Key trial
Nusinersen (Spinraza)	Antisense oligonucleotide that boosts SMN2-derived SMN protein	Intrathecal (spinal-fluid) injection	Dec 23, 2016	Jun 29, 2017	ENDEAR (Finkel et al., NEJM 2017)
Onasemnogene abeparvovec (Zolgensma)	One-time AAV9 gene-replacement therapy delivering a working SMN1 gene	Single IV infusion	May 24, 2019	2020	START/STR1VE (Mendell et al., NEJM 2017)
Risdiplam (Evrysdi)	Oral small molecule that modifies SMN2 splicing	Daily liquid taken at home	Aug 7, 2020	2021	FIREFISH / SUNFISH (Darras et al., NEJM 2021)

The evidence behind each is substantial. Nusinersen was tested in the ENDEAR trial, a randomized, sham-controlled study in infants with type 1 SMA. Significantly more treated infants reached motor milestones and were alive and free of permanent ventilation than controls, and the trial concluded that earlier treatment maximizes benefit. Onasemnogene abeparvovec, a one-time infusion, was studied in START, where all 15 treated infants were alive and free of permanent ventilation at 20 months, versus roughly 8% survival in an untreated historical group. The later phase 3 STR1VE trial confirmed superiority over natural-history data.

Risdiplam is the first oral, at-home therapy. In the FIREFISH study, a clinically meaningful share of infants with type 1 SMA achieved sitting without support, a milestone untreated type 1 patients do not reach. The companion SUNFISH trial showed risdiplam improved motor function versus placebo in older type 2 and type 3 patients, with benefit maintained at 24 months.

Two honest caveats belong here. First, regulators frame these as approved, disease-modifying therapies that change outcomes, not as a guaranteed universal “cure”. Second, access and cost differ sharply between the US and Canada. In Canada, public reimbursement is governed province by province, and national reviews have sometimes qualified who can start therapy, so coverage is not uniform. Which therapy fits a given child is an individualized decision for a specialist team, not something a report or an article can settle.

Section recap: Three approved therapies exist, nusinersen (FDA 2016), onasemnogene abeparvovec (FDA 2019), and risdiplam (FDA 2020), with Health Canada approvals following. They are disease-modifying, not a guaranteed cure, and Canadian coverage varies by province.

Why Presymptomatic Treatment Matters: NURTURE, SPR1NT, and Long-Term Data

The single research finding that most reframes SMA is this: treatment started before symptoms appear changes the trajectory. The NURTURE study treated genetically diagnosed but still-presymptomatic infants, those with 2 or 3 SMN2 copies, with nusinersen before symptoms began. In the interim analysis of 25 children, all were alive past the age when symptoms normally start, none needed a tracheostomy or permanent ventilation, all achieved sitting without support, and most reached walking. These are milestones that untreated SMA type 1 never reaches. A 5-year update reported continued durable benefit and no new safety concerns.

The same lesson holds for gene therapy. The SPR1NT trial gave the one-time AAV9 therapy to presymptomatic infants at risk of SMA. Infants with two SMN2 copies achieved independent sitting within a normal developmental window, again an outcome untreated type 1 patients never reach. Taken together, NURTURE and SPR1NT show that presymptomatic treatment can convert a once uniformly fatal infantile disease into one with normal or near-normal motor development in many treated infants. This is the biological reason newborn screening exists: the benefit is greatest before irreversible motor-neuron loss.

That connection is the heart of the story. Early identification, often through newborn screening, enables presymptomatic treatment, which materially changes the outcome. It is like fixing a small roof leak before the ceiling collapses: the same repair is far more effective when it happens early.

Honesty about the frontier matters just as much as the good news. Several questions are still under active study. The durability of one-time gene therapy over decades is not yet known. The best choice, sequence, or possible combination of the three therapies is still being worked out. Long-term safety and efficacy data continue to accrue in registries and extension studies through the mid-2020s. And outcomes for later-onset type 2 to type 4 and adult patients are still being characterized. The fair summary is “transformed, but not fully solved,” which is very different from either fatalism or a miracle-cure headline. A specialist can explain where the current evidence stands for a specific situation.

Section recap: NURTURE and SPR1NT show that treating infants before symptoms lets them reach milestones untreated SMA never reaches, which is why newborn screening matters. Long-term durability and the best therapy choice remain active research questions.

Family, Counseling, and Legal Context: Cascade Testing, NSGC, GINA, and Canada’s Law

Because SMA is recessive, one carrier result ripples through a family in a predictable way. Clinicians call the follow-up process cascade testing: checking relatives once a variant is known. Each full sibling of a carrier has about a 50% chance of also being a carrier, since siblings share parents. That figure is a starting point for deciding who might want testing, not a cause for alarm.

For a reader who is pregnant, the most actionable step is unambiguous: prompt SMN1 carrier testing for the reproductive partner. The result splits the path cleanly. If the partner is not a carrier, the couple’s children cannot inherit two non-working copies from the two of them, so they cannot have SMA from this pairing. If the partner is also a carrier, the 25% per-pregnancy figure from earlier applies, and prenatal options open up. A board-certified genetic counselor, found via the NSGC “Find a Genetic Counselor” tool at NSGC.org, can map who benefits from testing and interpret the residual risk from silent carriers.

The legal and insurance worries are common and reasonable, and the answer differs by country. In the United States, the Genetic Information Nondiscrimination Act of 2008, known as GINA, bars health insurers and employers from using genetic information in coverage, premium, underwriting, or employment decisions. The Affordable Care Act separately bars health-insurance discrimination based on pre-existing conditions. But GINA has a clear edge, and knowing where it stops is the whole point:

Protected by US GINA	Not protected by US GINA
Health insurance (coverage, premiums, underwriting)	Life insurance
Employment decisions (hiring, firing, pay, promotion)	Disability insurance
—	Long-term-care insurance

Canada’s framework is broader. The Genetic Non-Discrimination Act became law in 2017. It criminalizes requiring or using genetic-test results as a condition of goods, services, or contracts, and that explicitly includes insurance. On July 10, 2020, the Supreme Court of Canada upheld the Act as valid criminal law, so Canadian life, disability, and other insurers are barred from compelling or using genetic-test results. Because the persona lives in Canada, she has stronger statutory footing than a US reader, though provincial health plans and drug programs still govern access to the high-cost SMA therapies.

Disclosure to relatives has an emotional side too. Telling a sibling that you carry an SMN1 variant can feel awkward, yet it gives them useful reproductive information, since each has about a 50% chance of also carrying it. Many people find it easier to share the number than the label: “here is a figure that might matter for your family planning” often lands more like a gift than an accusation. A genetic counselor can help plan what to say and to whom. This is educational context and aggregated evidence, not legal or medical advice; for anything legal, consult a qualified professional, and for care, consult a clinician.

Section recap: Each sibling of a carrier has about a 50% chance of also carrying a variant, so partner testing is the urgent next step in pregnancy. US GINA protects health coverage and employment but not life or disability insurance, while Canada’s 2017 law is broader.

Frequently Asked Questions

Does an SMN1 carrier flag on 23andMe mean the reader will get SMA? No. A single SMN1 variant makes a person a healthy, unaffected carrier, because the other copy of the gene still works. SMA requires losing working SMN1 on both copies. The result is reproductive information, not a personal-health risk, and a genetic counselor can confirm and explain it.

Will the reader’s baby get SMA because one parent is a carrier and she is pregnant? Only if the reproductive partner is also an SMN1 carrier. In that case, each pregnancy carries a 25% chance of an affected child, so about 25 out of 100. Testing the partner promptly is the urgent next step during pregnancy.

What is SMN2 copy number and why does it matter? SMN2 is a backup gene that makes a small amount of SMN protein, and more SMN2 copies generally mean milder, later-onset SMA. Clinical molecular testing reports SMN2 copy number, but a 23andMe report does not.

Will the newborn be screened for SMA automatically? In the US, SMA has been on the RUSP since July 2018 and essentially all states screen newborns. In Canada, screening varies by province and is expanding, so a Canadian reader should confirm her own provincial program.

Is there a cure or approved treatment for SMA now? Three approved disease-modifying therapies exist: nusinersen (Spinraza, FDA 2016), onasemnogene abeparvovec (Zolgensma, FDA 2019), and risdiplam (Evrysdi, FDA 2020), with Health Canada approvals following. They change outcomes dramatically, especially when started before symptoms, but regulators do not describe them as a guaranteed universal cure.

Summary

The research is consistent and, for a worried carrier, largely reassuring. SMA is an autosomal recessive disorder of the single SMN1 gene, so a child needs two non-working copies to be affected. Carrying one variant, as a 23andMe report may flag, makes you a healthy carrier, and your own risk of the condition is essentially zero. Recurrence risk only enters the picture if your reproductive partner is also a carrier, in which case each pregnancy has a 25% chance of an affected child. If you are pregnant, everything else flows from that one partner-status question.

The practical path is clear. Clinical MLPA or qPCR testing counts SMN1 and SMN2 copies and confirms status, while consumer copy-number screens miss silent 2+0 carriers and rare mutations. Newborn screening now finds affected babies before symptoms in all US states and a growing number of Canadian provinces. On treatment, the honest picture is genuinely hopeful: three approved therapies, nusinersen, onasemnogene abeparvovec, and risdiplam, have transformed the outlook, and presymptomatic treatment in NURTURE and SPR1NT lets many infants reach milestones untreated SMA never reaches, even as long-term durability is still being studied. For your family, the most useful next steps are prompt partner testing and a conversation with a board-certified genetic counselor at NSGC.org. It also helps to know the legal picture: US GINA protects health coverage but not life insurance, while Canada’s 2017 law is broader.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. NIH / MedlinePlus Genetics. Spinal muscular atrophy — MedlinePlus Genetics. National Library of Medicine. https://medlineplus.gov/genetics/condition/spinal-muscular-atrophy/
2. OMIM #253300. Spinal Muscular Atrophy, Type I; SMA1 — OMIM Entry #253300. Johns Hopkins University. https://www.omim.org/entry/253300
3. Prior, Leach & Finanger. Spinal Muscular Atrophy — GeneReviews. NCBI Bookshelf, University of Washington. https://www.ncbi.nlm.nih.gov/books/NBK1352/
4. Finkel et al. (2017). Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy (ENDEAR). New England Journal of Medicine, 377(18):1723-1732. https://www.nejm.org/doi/full/10.1056/NEJMoa1702752
5. Mendell et al. (2017). Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy (START / AVXS-101). New England Journal of Medicine, 377(18):1713-1722. https://www.nejm.org/doi/full/10.1056/NEJMoa1706198
6. Darras et al. (2021). Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy (FIREFISH); Mercuri et al. (2022) SUNFISH. New England Journal of Medicine, 385:427-435; Lancet Neurology 21:42-52. https://www.nejm.org/doi/full/10.1056/NEJMoa2102047
7. De Vivo et al. (2019); Crawford et al. (2023). Nusinersen initiated presymptomatically (NURTURE) interim and 5-year update. Neuromuscular Disorders 29(11):842-856; Muscle & Nerve. https://www.nmd-journal.com/article/S0960-8966(19)31127-7/fulltext
8. Strauss et al. (2022). Onasemnogene abeparvovec for presymptomatic infants (SPR1NT Phase III). Nature Medicine, 28:1381-1389. https://www.nature.com/articles/s41591-022-01866-4
9. U.S. Food and Drug Administration. FDA approvals of SMA disease-modifying therapies (nusinersen 2016, onasemnogene abeparvovec 2019, risdiplam 2020). https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease
10. Health Canada / Drug and Health Products Portal; CADTH/CDA-AMC. Notices of Compliance and reviews for SMA therapies. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00268
11. HRSA Advisory Committee on Heritable Disorders in Newborns and Children. Recommended Uniform Screening Panel — SMA added July 2018. https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp
12. ACOG (2017, reaffirmed). Carrier Screening for Genetic Conditions — Committee Opinion No. 691. American College of Obstetricians and Gynecologists. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions
13. Feng et al. (2020). Enhanced Carrier Screening for Spinal Muscular Atrophy: Detection of Silent (SMN1: 2+0) Carriers. Laboratory Medicine, 51(4):408. https://academic.oup.com/labmed/article/51/4/408/5687020
14. NHGRI / genome.gov; Supreme Court of Canada (2020 SCC 17). Genetic Information Nondiscrimination Act (GINA) and Canada’s Genetic Non-Discrimination Act. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
15. National Society of Genetic Counselors (NSGC). Find a Genetic Counselor and carrier-screening / cascade-testing resources. https://www.nsgc.org/findageneticcounselor

Last updated: 2026-07-28

Author: Yu Mizuno, non-physician research editor. This article aggregates 15 sources from peer-reviewed medical literature and public health agencies (tier 1=10 / tier 2=5), including NIH/MedlinePlus, OMIM, GeneReviews, NEJM and Nature Medicine trials, FDA, Health Canada, HRSA/RUSP, ACOG, and NSGC resources.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🌐 日本語版: https://genelumen.com/ja/ja-neurogenetic/spinal-muscular-atrophy-smn1-carrier-inheritance-japan